Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Revolution Medicines (RVMD) Total Liabilities (2018 - 2025)

Historic Total Liabilities for Revolution Medicines (RVMD) over the last 8 years, with Q3 2025 value amounting to $655.0 million.

  • Revolution Medicines' Total Liabilities rose 23301.1% to $655.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $655.0 million, marking a year-over-year increase of 23301.1%. This contributed to the annual value of $293.1 million for FY2024, which is 2445.15% up from last year.
  • Revolution Medicines' Total Liabilities amounted to $655.0 million in Q3 2025, which was up 23301.1% from $564.2 million recorded in Q2 2025.
  • Revolution Medicines' Total Liabilities' 5-year high stood at $655.0 million during Q3 2025, with a 5-year trough of $89.0 million in Q2 2021.
  • For the 5-year period, Revolution Medicines' Total Liabilities averaged around $208.5 million, with its median value being $144.5 million (2022).
  • As far as peak fluctuations go, Revolution Medicines' Total Liabilities tumbled by 815.82% in 2023, and later skyrocketed by 23301.1% in 2025.
  • Revolution Medicines' Total Liabilities (Quarter) stood at $135.4 million in 2021, then fell by 6.41% to $126.7 million in 2022, then surged by 85.82% to $235.5 million in 2023, then grew by 24.45% to $293.1 million in 2024, then soared by 123.48% to $655.0 million in 2025.
  • Its Total Liabilities stands at $655.0 million for Q3 2025, versus $564.2 million for Q2 2025 and $287.2 million for Q1 2025.